Skip to content Skip to navigation Skip to footer

You are here:

Early treatment of patent ductus arteriosus with ibuprofen does not help to improve short-term outcomes for preterm babies

Baby-OSCAR

Baby-OSCAR is a multi-centre randomised controlled trial, co-ordinated from the National Perinatal Epidemiology Unit Clinical Trial unit (NPEU CTU) at the University of Oxford and aiming to find out whether or not a confirmed large Patent Ductus Arteriosus (PDA) in very premature babies should be treated with ibuprofen within 72 hours of birth. Funding is provided by the National Institute of Health Research (NIHR) Health Technology Assessment (HTA) programme (project reference 11/92/15) and sponsored by the University of Oxford.

Find out more

Recruitment total: 653
Recruitment to the Baby-OSCAR trial is now closed. We would like to thank all the families and site staff who took part.

Results from the Baby-OSCAR trial have shown that treatment with ibuprofen within 72 hours of birth does not improve survival rates or reduce occurrences of bronchopulmonary dysplasia for preterm babies born with a large patent ductus arteriosus. The results are published in the New England Journal of Medicine.

Baby-OSCAR

New evidence shows that early treatment of patent ductus arteriosus with ibuprofen does not help to improve short-term outcomes for preterm babies

Trial information

Connect with us

Support